Drug Trial Radar · NCT07191535
Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Mar 1, 2027
Primary completion
Jan 1, 2028
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Foresee Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- QPS Holdings LLC
- First posted
- Sep 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study explores a potential new treatment for adults with moderate-to-severe asthma using a drug called linvemastat, which targets an enzyme linked to lung inflammation. Despite using standard asthma medications, many patients still struggle with symptoms, so researchers are testing whether linvemastat can improve lung function and reduce flare-ups. In a carefully controlled trial, participants receive either one of two doses of the drug or a placebo, while continuing their usual treatments. Over 16 weeks, scientists monitor breathing capacity, symptom control, and safety to determine if linvemastat could offer a meaningful new option for asthma management.
Conditions
- Asthma (Diagnosis)
- Pulmonary Function
- Moderate-to-Severe Asthma
Interventions
linvemastatDrug
Matrix Metalloproteinase-12 inhibitor
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The mean change in trough FEV1 assessed by central spirometryTime frame: Baseline to Week 16
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.